We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

By LabMedica International staff writers
Posted on 28 Jul 2025

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if growths are malignant or benign. More...

This process can be invasive, costly, and time-consuming. Traditional diagnostic methods often involve blood draws or surgical biopsies, making them inaccessible for routine, rapid screening. Detecting melanoma early is crucial to improving outcomes, but limitations in current testing options delay diagnosis and increase patient anxiety. Now, researchers have developed a skin patch and test strip that allow for non-invasive, rapid detection of melanoma without the need for a biopsy or blood sample.

ExoPatch, developed by researchers at the University of Michigan (Ann Arbor, MI, USA), is a silicone patch embedded with star-shaped microneedles that are just 0.6 mm long. These microneedles are coated with a gel containing Annexin V protein that attracts and captures exosomes, tiny vesicles released by cells from interstitial fluid in the epidermis. Once applied to the skin, the microneedles painlessly penetrate only the topmost layer without drawing blood. After 15 minutes, the patch is removed and placed in acid, dissolving the gel and releasing the exosomes into a solution. A test strip, similar to an at-home COVID-19 test, is then dipped into the solution: two lines indicate the presence of melanoma exosomes, while one line indicates a negative result.

The ExoPatch was first validated on pig skin samples due to their similarity to human skin, with microscopy confirming microneedle penetration of 350 to 600 nanometers well within the epidermis. The system was then tested on tissue samples from mice, half of which had been injected with human melanoma tumor fragments. The patch successfully adhered to exosomes in the 30 to 150 nanometer range and was able to distinguish between melanoma and healthy tissue with a 3.5-fold darker test line for melanoma samples. The findings, published in Biosensors and Bioelectronics, showed that the patch isolated 11.5 times more exosomal protein from melanoma tissues, indicating high specificity. Future plans include a pilot study in humans followed by clinical trials. The gel coating of the ExoPatch could also be modified to detect exosomes from other solid tumors such as lung, breast, colon, prostate, and brain cancers.

“This is the first patch designed to capture disease-specific exosomes from fluid under the skin. The potential applications are huge,” said Sunitha Nagrath, co-corresponding author of the study.

Related Links:
University of Michigan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.